- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03609996
Retrospective Review of Proliferative Diabetic Retinopathy Patients
A Retrospective Review of Patients With Proliferative Diabetic Retinopathy and Regression of PDR After Treatment With Ranibizumab
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Current standard treatment for Proliferative Diabetic Retinopathy (PDR) is panretinal photocoagulation (PRP), but this treatment is inherently destructive and has several potential adverse effects on aspects of visual function, including constriction of peripheral visual fields and decreases in night vision, contrast sensitivity and color perception. Thus, therapeutic alternatives that might delay or obviate the need for PRP are desirable. It has been demonstrated that retinal neovascularization from PDR is highly responsive to anti-VEGF therapy, but it is unclear how long regression of retinal neovascularization is sustained after anti- VEGF therapy is halted in clinical practice.
It is possible that intravitreal ranibizumab treatment could prevent laser-associated vision loss by precluding the need for PRP as long as the eye continued to receive ranibizumab. Even if ranibizumab treatment was discontinued, it is possible that initial treatment with anti-VEGF therapy might improve visual outcomes substantially by delaying or preventing the need for PRP, and the infrequent frequency of administration of ranibizumab for DME (median 2 to 3 times in the second year of treatment) after the DME initially has resolved on anti-VEGF therapy suggests that monthly ranibizumab might not be needed to achieve control of PDR.
The Diabetic Retinopathy Clinical Research Network (DRCR network) is currently evaluating intravitreal ranibizumab treatment to see if can prevent laser-associated vision loss by precluding the need for PRP as long as the eye continued to receive ranibizumab. However, intravitreal injections carry the risk of serious complications. Ophthalmic complications include endophthalmitis in 2% of all injected patients cumulatively. Endophthalmitis is a vision threatening and can cause severe and permanent vision loss and even loss of the eye. Other complications include vitreous hemorrhage, retinal detachment, uveitis and glaucoma. This study will evaluate ranibizumab usage as the primary treatment for PDR in a busy private clinical practice.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
- Elman Retina Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >= 18 years Individuals <18 years old are not being included because PDR is so rare in this age group that the diagnosis of PDR may be questionable.
Diagnosis of diabetes mellitus (type 1 or type 2)
Any one of the following will be considered to be sufficient evidence that diabetes is present:
- Current regular use of insulin for the treatment of diabetes
- Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes
- Documented diabetes by ADA and/or WHO criteria (see Procedures Manual for definitions
- Presence of PDR which the investigator has treated the study eye(s) with ranibizumab
Exclusion Criteria:
- History of prior panretinal photocoagulation prior to initiating ranibizumab
Tractional retinal detachment involving the macula.
- A tractional retinal detachment is not an exclusion if it is outside of the posterior pole (not threatening the macula)
- History of vitrectomy prior to initiating ranibizumab
- Treatment with Ranibizumab within six months of treatment regimen
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PDR treated with Laser
|
Laser treatment for PDR
Intraviteral injection
|
PDR treated with Lucentis
|
Laser treatment for PDR
Intraviteral injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical regression of neovascularization not requiring further treatment beyond RBZ
Time Frame: 2009-2018
|
Clinical regression of neovascularization not requiring further treatment beyond RBZ
|
2009-2018
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Elman, Elman Retina Group, P.A.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Diabetes Complications
- Diabetes Mellitus
- Retinal Diseases
- Diabetic Retinopathy
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- ML29652
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proliferative Diabetic Retinopathy
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Peking University People's HospitalCompletedProliferative Diabetic RetinopathyChina
-
Charles C Wykoff, PhD, MDRegeneron PharmaceuticalsCompletedProliferative Diabetic RetinopathyUnited States
Clinical Trials on Panretinal Photocoagulation
-
Centre Hospitalier Universitaire DijonRecruiting
-
University of Sao Paulo General HospitalConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedDiabetic Retinopathy
-
Federal University of São PauloUnknown
-
Baqiyatallah Medical Sciences UniversityCompletedDiabetes Mellitus, Type 2Iran, Islamic Republic of
-
Odense University HospitalUniversity of Southern Denmark; Velux FondenCompletedDiabetes | Proliferative Diabetic Retinopathy | PDRDenmark
-
Odense University HospitalMoorfields Eye Hospital NHS Foundation Trust; University of Southern Denmark; Yamagata University and other collaboratorsCompletedProliferative Diabetic RetinopathyDenmark
-
Hermann Eye CenterEyetech PharmaceuticalsCompletedDiabetic Retinopathy | Iris NeovascularizationUnited States
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruitingNon Proliferative Diabetic RetinopathyChina
-
Association for Innovation and Biomedical Research...CompletedDiabetes Mellitus Type II | Diabetes Mellitus Type I | High Risk Proliferative Diabetic RetinopathyPortugal
-
Asociación para Evitar la Ceguera en MéxicoCompletedBruch Rupture | Choroidal DetachmentMexico